SavedAdd your journal

Journals / Retina-Vitreus / 2010 / Cilt: 18 - Sayı: 1

Our Results of Intravitreal Bevacizumab Treatment for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Yaşa Bağlı Maküla Dejenerasyonuna İkincil Gelişen Koroid Neovaskülarizasyonlarında İntravitreal Bevacizumab Tedavi Sonuçlarımız

ELVAN ALPER ŞENGÜL
Özgür ARTUNAY
Erdal YÜZBAŞIOĞLU
Rıfat RAİSER
Amber ŞENEL
Halil BAHÇECİOĞLU
Pages
18–22
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

After 12 month follow-up CMT results were 70 eyes (67.3%) decreased by 100 ?m and more, 27 eyes (26.0%) had no change and 7 eyes (6.7%) increased by 100 ?m and more.Conclusions: Intravitreal bevacizumab provides significant anatomic and functional improvement compared baseline in choroidal neovascularization due to ARMD

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To report efficacy and our results of intravitreal bevacizumab injection for choroidal neovascularization due to age-related macula degeneration (ARMD).Materials and Methods: One hundred four eyes of 79 patients were received 528 injections of 1.25 mg/0.05 mL intravitreal bevacizumab and followed at least one year.
📊
Key Findings & Data:Every patient has received injections once a month for 3 consecutive months.
💡
Conclusion & Impact:After 12 month follow-up CMT results were 70 eyes (67.3%) decreased by 100 ?m and more, 27 eyes (26.0%) had no change and 7 eyes (6.7%) increased by 100 ?m and more.Conclusions: Intravitreal bevacizumab provides significant anatomic and functional improvement compared baseline in choroidal neovascularization due to ARMD
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To report efficacy and our results of intravitreal bevacizumab injection for choroidal neovascularization due to age-related macula degeneration (ARMD).Materials and Methods: One hundred four eyes of 79 patients were received 528 injections of 1.25 mg/0.05 mL intravitreal bevacizumab and followed at least one year. Every patient has received injections once a month for 3 consecutive months. Intravitreal reinjections of bevacizumab were administered according to visual acuity (VA) measurements, fundus fluorescein angiography (FFA) and optic coherens tomography (OCT) results.Results: According to mean VA results, 48 eyes (46.2%) had an increase of 5 letters and more. Fifty eyes (48.1%) had no change and 6 eyes (5.7%) had a decrease of 5 letters and more in 3th month. After 12 month follow-up VA results were 43 eyes (41.3%) had an increase of 5 letters and more, 53 eyes (50.9%) had no change and 8 eyes (7.7%) had a decrease of 5 letters and more,. Central macular thickness (CMT) were; in 75 eyes (72.1%) decreased by 100 ?m and more, in 23 eyes (22.1%) had no change and in 6 eyes (5.8%) increased by 100 ?m and more in 3th month. After 12 month follow-up CMT results were 70 eyes (67.3%) decreased by 100 ?m and more, 27 eyes (26.0%) had no change and 7 eyes (6.7%) increased by 100 ?m and more.Conclusions: Intravitreal bevacizumab provides significant anatomic and functional improvement compared baseline in choroidal neovascularization due to ARMD

Özet

Amaç: Yaşa bağlı maküla dejenerasyonuna bağlı gelişen koroid neovaskülarizasyonunda intravitreal bevacizumabın etkinliğini göstermek ve sonuçlarımızı bildirmek.Gereç ve Yöntem: Yetmiş dokuz hastanın, 104 gözüne 528 intravitreal bevacizumab (1.25 mg/0.05 mL) enjeksiyonu uygulanmıştır ve hastalar en az bir yıl süreyle takip edilmiştir. Her hastaya birer ay arayla 3 enjeksiyon yapıldıktan sonra hastaların görme keskinliği (GK), fundus floresein anjiyografi (FFA) ve optik koherens tomografi (OKT) sonuçları değerlendirilerek enjeksiyon tekrarına karar verilmiştir. Bulgular: ETDRS eşeli ile ölçülen görme keskinliklerine göre 3. ayda 5 harf ve üzeri artma gösteren 48 göz (%46.2), değişim göstermeyen 50 göz (%48.1) ve 5 harf ve üzeri düşme gösteren 6 göz (%5.7) olduğu tespit edilirken 12. ay sonunda ayda 5 harf ve üzeri artma gösteren 43 göz (%41.3), değişim göstermeyen 53 göz (%50.9) ve 5 harf ve üzeri düşme gösteren 8 göz (%7.7) bulundu. OKT ile belirlenen maküla kalınlıklarına göre 3. ayda 100 ?m ve üzeri azalma gösteren 75 göz (%72.1), değişme gözlenmeyen 23 göz (%22.1) ve maküla kalınlığında artma olan 6 göz (%5.8) olduğu bulunurken 12. ayda 100 ?m ve üzeri azalma gösteren 70 göz (%67.3), değişme gözlenmeyen 27 göz (%26.0) ve maküla kalınlığında artma olan 7 göz (%6.7) tespit edildi. Göz başına düşen ortalama enjeksiyon sayısı 5.08 idi.Sonuç: Yaşa bağlı maküla dejenerasyonuna bağlı gelişen koroid neovaskülarizasyonunda intravitreal bevacizumab tedavisi ile anatomik ve fonksiyonel açıdan başarılı sonuçlar alınmıştır

🔖

Cite This Article

ŞENGÜL, E. A., ARTUNAY, Ö., YÜZBAŞIOĞLU, E., RAİSER, R., ŞENEL, A., BAHÇECİOĞLU, H. (2010). Our Results of Intravitreal Bevacizumab Treatment for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Retina-Vitreus, Cilt: 18 - Sayı: 1, 18–22. https://ajindex.com/articles/305136

References (15)

  1. Avastin (Product monograph): Gardiner-Caldwell Communicati-ons Mississauga, Ontario: Hoffmann-La Roche Ltd. 2005
  2. Funatsu H, Yamashita H, Noma H, et al.: Aqueous humor levels of cytokines are related to vitreous levels and progression of dia-betic retinopathy in diabetic patients. Graefes Arch Clin Exp Oph-thalmol. 2005;243:3-8
  3. Ng EW, Adamis AP.: Targeting angiogenesis, the underlying di-sorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40:352-368
  4. Aiello LP, Avery RL, Arrigg PG, et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and ot-her retinal disorders. N Engl J Med. 1994;331:1480-1487
  5. Avery RL.: Regression of retinal and iris neovascularization af-ter intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26: 352-354
  6. Avery RL, Pieramici DJ, Rabena MD et al.: Intravitreal bevacizu-mab (Avastin) for neovascular age-related macular degenerati-on. Ophthalmology. 2007;113:363-372
  7. Bashshur ZF, Haddad ZA, Schakal A, et al.: Intravitreal beva-cizumab for treatment of neovascular age-related macular de-generation: a one-year prospective study. Am J Ophthalmol. 2008;145:249-256
  8. Arevalo JF, Fromow-Guerra J, Sanchez JG, et al.: Primary intra-vitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Re-tina. 2008;28:1387-1394
  9. Forte R, Cennamo G, Vecchio EC, et al.: Bevacizumab in ma-cular edema: functional and anatomic changes in a prospective case series. Retina. 2009;29:941-948
  10. Ferrara N.: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581-611
  11. Mulcahy MF, Benson AB.: III. Bevacizumab in the treatment of co-lorectal cancer. Expert Opin Biol Ther. 2005;5:997-1005
  12. FDA Medwatch. Barron H.: Genentech. Important drug war-ning [letter]. Available at: http://www.fda.gov/medwatch/ SA-FETY/2005/Avastin_dearhcp.pdf. Accessed October 10, 2005
  13. Rosenfeld PJ, Moshfeghi AA, Puliafito CA.: Optical coheren-ce tomography findings after intravitreal injection of bevacizu-mab (Avastin) for neovascular age-related macular degenerati-on. Ophthalmic Surg Lasers Imaging. 2005;36:331-335
  14. Reichel E.: Intravitreal bevacizumab for choroidal neovasculari-zation and cystoid macular edema: a cost-effective treatment? Ophthalmic Surg Lasers Imaging. 2005;36:270-271
  15. Spaide RF, Laud K,